Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a clinical-stage biotech company specializing in RNA interference (RNAi) therapeutics. The company is headquartered in Pasadena, California, and was founded in 2009. Arrowhead develops innovative medicines that target the underlying cause of disease by silencing specific genes.
Arrowhead's proprietary TRiM™ platform enables precise delivery of RNAi therapeutics:
Trigger molecules: Proprietary RNAi constructs
Targeting ligands: Various tissue-specific ligands for organ targeting
Structural components: Optimized for stability and efficacy
Delivery system: Conjugate-based delivery without viral vectors
Key Advantages
Tissue targeting: Selective delivery to liver, lung, tumors, and other tissues
Durability: Extended duration of gene silencing
Safety profile: Reduced off-target effects
Manufacturing: Scalable, cost-effective production
Versatility: Applicability to multiple disease areas
Pipeline Focus
Current Focus Areas
...
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals (NASDAQ: ARWR) is a clinical-stage biotech company specializing in RNA interference (RNAi) therapeutics. The company is headquartered in Pasadena, California, and was founded in 2009. Arrowhead develops innovative medicines that target the underlying cause of disease by silencing specific genes.
| Year | Milestone | |------|-----------| | 2014 | IPO on NASDAQ | | 2019 | First CNS program IND submission | | 2021 | Positive Phase 2 data for ARO-APOC3 | | 2023 | FDA Fast Track for ARO-APOC3 | | 2024 | Multiple Phase 3 trials initiated |